Gabapentin
Product Images NDC 33358-154

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 33358-154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rxchange Co., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin (Gabapentin)

Gabapentin 600 mg tablets packaging label by RxChange Co. The label shows item number 0154-00 and NDC 33358-154-00 for a bottle of 100 tablets. Tablets are described as white, film-coated, modified-capsule-shaped, and bisected. Storage instructions indicate to keep at controlled room temperature 68 to 77°F in a tight or light-resistant container. Manufacturer is InvaGen Pharmaceuticals, Inc., Hauppauge, NY.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\figure_01.jpg (C13551d6 Figure 01)

Chemical structure of gabapentin, featuring a cyclohexane ring attached to an aminomethyl group and an acetic acid group as shown in the diagram.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_02.jpg (C13551d6 Figure 02)

A line graph showing weekly mean pain scores over eight weeks comparing placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a significant decrease in pain scores compared to placebo throughout the period.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_03.jpg (C13551d6 Figure 03)

A line graph showing weekly mean pain scores over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph includes a 3-week dose titration period and a 4-week fixed dose period. Pain scores decrease more for Gabapentin groups than placebo.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_04.jpg (C13551d6 Figure 04)

A bar chart comparing the percentage of responders with at least 50% reduction in pain score at the endpoint of controlled PHN studies. It displays data from two studies with groups labeled PBO, GBP 3600, GBP 1800, and GBP 2400, showing higher responder percentages in GBP groups versus placebo. Statistical significance is indicated with p-values under 0.01 and 0.001.*

FDA Label Image

D:\work\elabel\2012.10\10.25\1\gabapentin_25-oct-2012\figure_05.jpg (C13551d6 Figure 05)

A scatter plot shows the responder rate difference (%) from placebo by daily dose (mg) of Gabapentin across three adjunctive therapy studies labeled a, b, and c. The x-axis ranges from 600 to 1800 mg, and the y-axis depicts difference percentages from 2% to 22%, with distinct markers for each study.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.